J&J's Zytiga Boosts Prostate Drug Market

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

June 2 (Bloomberg) -- Bloomberg's Shannon Pettypiece reports on Johnson & Johnson’s Zytiga, the first prostate cancer pill to win U.S. marketing approval in a family of treatments that offer new ways to stymie the male hormones that fuel tumor growth. Similar medicines from Medivation Inc. and Takeda Pharmaceutical Co. will report study results this weekend at the American Society of Clinical Oncology meeting in Chicago. Pettypiece speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change